Medwave seeks buyer
This article was originally published in The Gray Sheet
Maker of non-invasive blood pressure measurement and monitoring systems is exploring "strategic alternatives," including the possible sale of the company, Medwave says April 10. The firm disclosed in its recent annual report that continued net losses and an accumulated deficit of about $34 million "raise substantial doubt about the company's ability to continue as a going concern." In January, Medwave received a delisting warning from the Nasdaq stock market when its share price traded below $1 for more than 30 days in a row...
You may also be interested in...
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.
As Nestlé continues to expand its presence in the VMS market it will not take a brand popular in one country and “force” that name on consumers in a different part of the world, says CEO Mark Schneider.
Lupin has claimed a first with a UK approval for a rival to Fostair. The Indian company has told Generics Bulletin that it is planning to roll out the Luforbec branded generic later this year.